Avalyn is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including Idiopathic Pulmonary Fibrosis (IPF) and other Interstitial Lung Diseases (ILD). ILDs are characterized by pulmonary scarring, a decline in lung function, reduced exercise capacity and quality of life, and increased mortality risk. Currently approved therapeutic options slow disease progression but are associated with significant side effects, which restrict their use and dosing. Avalyn is developing a pipeline of inhaled medicines to reduce systemic exposure and deliver the medication directly to the disease site. AP01, Avalyn’s lead candidate, is a Phase 2b-ready inhaled formulation of pirfenidone optimized for direct lung delivery via inhalation. In a recent clinical study of two doses assessed in 91 individuals with IPF, AP01 demonstrated the potential to improve efficacy and safety over existing therapy. 

 

At Avalyn, we are driven by a passion for helping patients. We are a spunky, entrepreneurial start-up focusing on rare lung diseases. Our employees want to make a difference in our patient’s lives; some have direct ties to people living with severe lung diseases.

At Avalyn, we are building a culture that encourages collaboration, innovation, and professional development. Our workplace encourages supportive feedback to fosters creative thinking and freedom of expression, resulting in an empowering atmosphere where people enjoy coming to work.

If you are also driven by a passion for helping patients, embrace our mission, and are inspired to join our quest, we are interested in hearing from you.